Effect of Fra-2 expression on tumour immunogenicity and prognosis in KRAS-mutant lung adenocarcinoma

被引：0

作者：

Ucero, A. C. ^{[1
]}

Gutierrez Perez, M. ^{[1
]}

Zazo, A. ^{[1
]}

Bakiri, L. ^{[2
,3
]}

Wagner, E. F. ^{[2
,3
]}

Paz-Ares, L. ^{[1
]}

机构：

[1] Univ Complutense, Hosp Univ 12 Octubre, Translat Oncol & Lung Canc Unit,Physiol & Med Dep, CNIO H12o Lung Canc Unit & Ciberonc, Madrid, Spain

[2] Med Univ Vienna, Dept Lab Med, Inst Canc Res, Vienna, Austria

[3] Med Univ Vienna, Dept Dermatol, Inst Canc Res, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1281P

引用

页码：S740 / S740

页数：1

共 50 条

[1] Osteopontin drives KRAS-mutant lung adenocarcinoma
Giopanou, Ioanna
Kanellakis, Nikolaos, I
Giannou, Anastasios D.
Lilis, Ioannis
Marazioti, Antonia
Spella, Magda
Papaleonidopoulos, Vassilios
Simoes, Davina C. M.
Zazara, Dimitra E.
Agalioti, Theodora
Moschos, Charalampos
Magkouta, Sophia
Kalomenidis, Ioannis
Panoutsakopoulou, Vily
Lamort, Anne-Sophie
Stathopoulos, Georgios T.
Psallidas, Ioannis
CARCINOGENESIS, 2020, 41 (08) : 1134 - 1144
[2] Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
Boiarsky, D.
Lydon, C. A.
Chambers, E. S.
Sholl, L. M.
Nishino, M.
Skoulidis, F.
Heymach, J., V
Luo, J.
Awad, M. A.
Janne, P. A.
Van Allen, E. M.
Barbie, D. A.
Vokes, N. I.
ANNALS OF ONCOLOGY, 2023, 34 (07) : 589 - 604
[3] CONCURRENT TARGETABLE GENETIC DRIVER ALTERATIONS IN KRAS-MUTANT LUNG ADENOCARCINOMA
Paul, D.
Rafael, O. C.
EUROPEAN JOURNAL OF CANCER, 2016, 60 : E15 - E16
[4] Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma
Taus, Alvaro
Camacho, Laura
Rocha, Pedro
Hernandez, Ainhoa
Longaron, Raquel
Clave, Sergi
Fernandez-Ibarrondo, Lierni
Salido, Marta
Hardy-Werbin, Max
Fernandez-Rodriguez, Concepcion
Albanell, Joan
Bellosillo, Beatriz
Arriola, Edurne
ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (05): : 323 - 329
[5] IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma
Vreka, Malamati
Lilis, Ioannis
Papageorgopoulou, Maria
Giotopoulou, Georgia A.
Lianou, Marina
Giopanou, Ioanna
Kanellakis, Nikolaos I.
Spella, Magda
Agalioti, Theodora
Armenis, Vasileios
Goldmann, Torsten
Marwitz, Sebastian
Yull, Fiona E.
Blackwell, Timothy S.
Pasparakis, Manolis
Marazioti, Antonia
Stathopoulos, Georgios T.
CANCER RESEARCH, 2018, 78 (11) : 2939 - 2951
[6] Impact of co-mutations on the immune microenvironment of KRAS-mutant lung adenocarcinoma
Skoulidis, Ferdinandos
Denning, Warren
Diao, Lixia
Tong, Pan
Fan, You Hong
Papadimitrakopoulou, Vassiliki
Izzo, Julie
Behrens, Carmen
Kadara, Humam
Cuentas, Edwin R. Parra
Canales, Jaime Rodriguez
Wang, Jing
Byers, Lauren A.
Wistuba, Ignacio I.
Heymach, John V.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S13 - S14
[7] MAPK regulation of an innate immune response in KRAS-mutant lung adenocarcinoma.
Sisler, Daniel
Korpela, Sean
Gurule, Natalia
Hinz, Trista
Marek, Lindsay
Bullock, Bonnie
Li, Howard
Joshi, Molishree
Sempeck, Colin
Nemenoff, Raphael
Heasley, Lynn
MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 76 - 77
[8] Navel insights into the RTK-dependent metastatic phenotype of KRAS-mutant lung adenocarcinoma
Cooke, Mariana
MOLECULAR & CELLULAR ONCOLOGY, 2021, 8 (06)
[9] Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Best, Sarah A.
Ding, Sheryl
Kersbergen, Ariena
Dong, Xueyi
Song, Ji-Ying
Xie, Yi
Reljic, Boris
Li, Kaiming
Vince, James E.
Rathi, Vivek
Wright, Gavin M.
Ritchie, Matthew E.
Sutherland, Kate D.
NATURE COMMUNICATIONS, 2019, 10 (1)
[10] Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Sarah A. Best
Sheryl Ding
Ariena Kersbergen
Xueyi Dong
Ji-Ying Song
Yi Xie
Boris Reljic
Kaiming Li
James E. Vince
Vivek Rathi
Gavin M. Wright
Matthew E. Ritchie
Kate D. Sutherland
Nature Communications, 10

← 1 2 3 4 5 →